Evidence map›Paper›PMID 34260038›Full record

ArticleInfectious diseases and therapy2021

Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital.

Elisabeth Paramythiotou, George Dimopoulos, Nikolaos Koliakos, Maria Siopi, Sophia Vourli, Spyros Pournaras, Joseph Meletiadis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Accelerating the understanding ofCurrent research in microbial sciences · 2024
    Review
  9. Article
  10. COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023
    Review
  11. Article
  12. Review
  13. Isavuconazole for COVID-19-Associated Invasive Mold Infections.Journal of fungi (Basel, Switzerland) · 2022
    Review
  14. Review
  15. Possible COVID-19-Associated Pulmonary Aspergillosis Due toAntibiotics (Basel, Switzerland) · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elisabeth Paramythiotou2nd Department of Critical Care, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
George Dimopoulos2nd Department of Critical Care, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos Koliakos2nd Department of Critical Care, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Maria SiopiClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 1 Rimini str, Haidari 124 62, Athens, Greece.
Sophia VourliClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 1 Rimini str, Haidari 124 62, Athens, Greece.
Spyros PournarasClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 1 Rimini str, Haidari 124 62, Athens, Greece.
Joseph MeletiadisClinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 1 Rimini str, Haidari 124 62, Athens, Greece. jmeletiadis@med.uoa.gr.ORCID http://orcid.org/0000-0002-8869-1509
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInvasive pulmonary aspergillosis is an emerging complication among intensive care unit (ICU) patients with COVID-19 (CAPA). In the present study, all CAPA cases during the first year of the pandemic were reviewed in critically ill patients at a 650-bed tertiary Greek COVID-19 reference hospital.

methodsData regarding patients admitted to the ICU of Attikon Hospital in Athens, Greece, between 22 March 2020 and 28 February 2021 with a positive PCR for SARS-CoV-2 infection were reviewed. Clinical and microbiological records were analysed including demographic, clinical, laboratory and radiological features, treatment and outcomes. CAPA was determined according to the recent 2020 ECMM/ISHAM definitions.

resultsA total of 179 patients were admitted in the ICU and 6 (3.3%) patients were diagnosed with CAPA (4 probable and 2 possible CAPA) with 5/6 with co-infection with multidrug-resistant (MDR) gram-negative pathogens. No patient had a history of immunosuppression. All suffered from acute respiratory distress syndrome. The median (range) time from intubation to diagnosis was 6 (1-14) days. Five patients had positive Aspergillus cultures in bronchial secretions (1 A. fumigatus, 1 A. flavus, 1 A. fumigatus + A. flavus, 1 A. fumigatus + A. terreus and 1 A. terreus) while culture was negative in one patient. All isolates were susceptible to antifungal drugs. Serum galactomannan (GM), pan-Aspergillus PCR and (1,3)-β-D-glucan (BDG) were positive in 4/6 (67%), 5/6 (83%, 3/5 in two consecutive samples) and 4/6 (67%, in consecutive samples) patients, respectively. GM and PCR positive bronchial secretions had GM indices > 9.95 and PCR C

conclusionThe incidence of CAPA in ICU patients was 3.3% and it was associated with approximately a 17% attributable mortality in the setting of MDR gram-negative pathogen co-infections.

Indexed as

ARDSAspergillosisCOVID-19Lung infectionMDR gram-negative co-infections

Identifiers

PMID34260038
PMCPMC8278173
OpenAlexW3179897387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.